Qualera surfaces risk before it becomes a 483.

Qualera™ is audit intelligence built for medical device quality. It reads your quality system documents and records the way an FDA investigator would, and shows you where the gaps are while you still have time to close them. An experienced MB&A auditor decides every finding before it reaches you.

TodayAvailable through MB&A, priced per auditNovember 2026Platform opens to a limited pilot group2027Wider availability

What changed on February 2, 2026

Your internal audits used to stay inside the building. Under the QMSR, FDA can ask to read them.

The Quality Management System Regulation brought ISO 13485 into U.S. law and changed what an inspection looks like. The records you once wrote for yourselves are now evidence, and the way investigators move through your system has changed with them.

Read FDA's QMSR page

  • The exemption

    Audit reports are no longer off limits

    The old rule kept internal audit, supplier audit and management review reports out of an investigator's hands. The QMSR dropped that exception.

  • The method

    QSIT is retired

    Investigators now work from Compliance Program 7382.850, which follows risk across the whole quality system instead of walking one subsystem at a time.

  • The pace

    FDA reads faster now

    FDA rolled out its own generative AI tool, Elsa, in 2025 and said it would help identify high-priority inspection targets. FDA's announcement

  • The team

    The bar went up. Most quality teams didn't get bigger.

    The same people who run complaints, CAPA and supplier quality are now expected to be inspection ready on all of it, all the time.

Where the risk hides

The findings that become warning letters rarely live in one document.

A complaint trend that never reached CAPA. A design change that skipped the risk file. A supplier whose nonconformances stopped showing up in management review. Each record looks fine on its own. The problem is in the connection, and that is the hardest thing for a busy team to see.

Qualera is built to look across your quality system the way an investigator does, and to show its work every time.

QFinding 07 of 23Example Medical, Inc. (fictional)
ISO 13485:2016, clause 8.2.221 CFR 820.10Draft severity: Major

Complaint trends are reviewed every month, but no trend has opened a CAPA in 14 months.

RequirementClause 8.2.2 requires the organization to decide whether a complaint needs corrective or preventive action, and to record that decision.
EvidenceComplaint trends shall be reviewed monthly by the Quality Manager. Escalation to CAPA is at the Quality Manager's discretion.SOP QP-8.2-02, Rev D, section 5.4
Also seen in14 monthly complaint trend summaries (January 2025 to February 2026) and the CAPA log, which has no complaint-sourced entries in that period.
Lead auditor decision: kept, severity changed to Minor

Illustration with a fictional company and records. Real findings follow the same format: the clause, the passage it comes from, and an auditor's decision.

Human in command

The platform finds. The auditor decides.

Qualera doesn't hand you a score and walk away. Every finding goes to an experienced MB&A auditor, who keeps it, changes it or throws it out. Nothing reaches you on the platform's say-so alone.

That's how regulated work should be done, and it's what an investigator will expect your own audits to look like. Every finding cites the clause and the passage behind it, so you and your auditor can check the reasoning against the record yourselves. Every audit comes back in the same report structure, so this year's results line up with last year's.

How the platform works

As we consolidate our legacy manufacturing sites, we wanted confidence that our QMS and teams were ready for increased regulatory scrutiny. The mock FDA inspection combined experienced auditor review with Qualera, MB&A’s AI platform, to assess our QMS and more than 500 records, helping us identify opportunities before an actual inspection and leaving us better prepared for upcoming regulatory audits.
VP, Quality & Regulatory AffairsNeurodiagnostic medical device company

Where device teams use it

Before the moments that matter most.

Most teams bring us in when something is coming: an inspection, a supplier decision, a deal. The earlier the read, the more time you have to fix what it finds.

  • Inspection

    Your first FDA inspection under the QMSR

    A mock inspection against your QMS and records, run before the real one, so the first time you hear a finding it comes from your own side of the table.

    Mock FDA inspections
  • The shift

    Moving from Part 820 to the QMSR

    A gap assessment against ISO 13485:2016 and the QMSR that shows where a system built for the old checklist falls short of the new one.

    QMSR gap assessments
  • Suppliers

    Supplier audits that start before anyone travels

    Machining, coating, sterilization and packaging partners send their documents first. The visit then goes straight to the real gaps.

    Supplier audits
  • Internal

    Internal audits and management review

    Now that FDA can read them, they need to hold up as evidence. We help them read that way.

    Internal audits
  • Deals

    Fundraising or acquisition

    Quality due diligence that holds up when an investor or acquirer asks what FDA will find after the deal closes.

    Quality due diligence

Who it's for

Built for the people who answer for the quality system.

  • Quality leaders

    VPs of quality, QA/RA directors and management representatives

    Know what an investigator will find before they do, and spend your team's hours on judgment instead of document hunting.

  • Supplier quality

    Supplier quality engineers and managers

    Dozens of suppliers, a few auditors and a CAPA list that never shrinks. Get a desk review of every supplier package in one report format.

  • Manufacturers

    Contract manufacturers and component suppliers

    Every OEM customer audits you. Find the gaps before they do, and hand them a record that is clean and cited.

  • Deal teams

    Investors, acquirers and operating partners

    Understand a device company's quality system before you own its FDA history.

More on who we serve

How to get it

Available now as an audit. Opening as a platform.

Today MB&A runs your audit with Qualera, priced per audit like any audit firm. You never need to touch the software. The platform itself opens to device teams in stages.

Spring 2026

First client audits

Run alongside MB&A's auditors on live client work.

September 2026

Launched

Available through MB&A as a service.

November 2026

Pilot group

The platform opens to a limited group of device teams. Seats are limited.

2027

Wider availability

Early-access members are first in line.

Monica Burt, founder and CEO of Qualera and MB&A

Founder

Built by someone who has spent 25 years on both sides of the audit table.

  • 300+ audits against FDA, ISO, MDSAP and other global regulations
  • Quality leadership at Medtronic, Smith & Nephew and Wright Medical
  • Took part in the MDSAP pilot

Monica Burt founded MB&A in 2019 and Qualera in 2025. She built Qualera to give device teams the kind of review she would want before any inspection: thorough, cited, and decided by an auditor who has been in the room.

About Qualera

Start here

Tell us about your device and your next audit or inspection.

We'll tell you what Qualera can do for your team right now, and where you'd fit in the platform pilot group.